Title: Anti-tumor activity and mechanism of action for a cyanoaziridine-derivative, AMP423.
Journal: Cancer chemotherapy and pharmacology 20120401
Title: Imexon induces an oxidative endoplasmic reticulum stress response in pancreatic cancer cells.
Journal: Molecular cancer research : MCR 20120301
Title: Chemistry and pharmacology of imexon and related cyanoaziridines.
Journal: Current medicinal chemistry 20120101
Title: Interaction of dacarbazine and imexon, in vitro and in vivo, in human A375 melanoma cells.
Journal: Anticancer research 20110901
Title: Imexon enhances gemcitabine cytotoxicity by inhibition of ribonucleotide reductase.
Journal: Cancer chemotherapy and pharmacology 20110101
Title: A phase I trial of imexon, a pro-oxidant, in combination with docetaxel for the treatment of patients with advanced breast, non-small cell lung and prostate cancer.
Journal: Investigational new drugs 20101001
Title: A phase 1-2 study of imexon plus dacarbazine in patients with unresectable metastatic melanoma.
Journal: Cancer 20100801
Title: Combined phase I/II study of imexon (AOP99.0001) for treatment of relapsed or refractory multiple myeloma.
Journal: Anti-cancer drugs 20100801
Title: A phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic cancer.
Journal: Cancer chemotherapy and pharmacology 20100701
Title: Redox-directed cancer therapeutics: molecular mechanisms and opportunities.
Journal: Antioxidants & redox signaling 20091201
Title: Imexon augments sensitivity of human lymphoma cells to ionizing radiation: in vitro experimental study.
Journal: Anticancer research 20091101
Title: Inhibition of protein synthesis by imexon reduces HIF-1alpha expression in normoxic and hypoxic pancreatic cancer cells.
Journal: Investigational new drugs 20090201
Title: New analytical techniques to facilitate preformulation screening in propellant systems.
Journal: International journal of pharmaceutics 20070801
Title: The antitumor agent imexon activates antioxidant gene expression: evidence for an oxidative stress response.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20070601
Title: Imexon-based combination chemotherapy in A375 human melanoma and RPMI 8226 human myeloma cell lines.
Journal: Cancer chemotherapy and pharmacology 20070501
Title: Phase I trial of imexon in patients with advanced malignancy.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070501
Title: Preclinical antitumor activity, pharmacokinetics and pharmacodynamics of imexon in mice.
Journal: Anti-cancer drugs 20061101
Title: Preformulation studies on imexon.
Journal: Drug development and industrial pharmacy 20060701
Title: Microsphere-based protease assays and screening application for lethal factor and factor Xa.
Journal: Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501
Title: Oxidative stress and apoptosis: a new treatment paradigm in cancer.
Journal: Frontiers in bioscience : a journal and virtual library 20060101
Title: Correlates of imexon sensitivity in human multiple myeloma cell lines.
Journal: Leukemia & lymphoma 20060101
Title: Targeting mitochondria emerges as therapeutic strategy.
Journal: Journal of the National Cancer Institute 20051221
Title: Rob Ashley of AmpliMed discusses the discovery and development of Imexon. Interview by Steve Carney.
Journal: Drug discovery today 20051015
Title: Compatibility and stability of Imexon in infusion devices and its in vitro biocompatibility.
Journal: Anti-cancer drugs 20050801
Title: LC-UV method development and validation for the investigational anticancer agent imexon and identification of its degradation products.
Journal: Journal of pharmaceutical and biomedical analysis 20050715
Title: Pharmaceutical development of a lyophilised dosage form for the investigational anticancer agent Imexon using dimethyl sulfoxide as solubilising and stabilising agent.
Journal: Journal of pharmaceutical sciences 20050501
Title: Induction of apoptosis and cell cycle arrest by imexon in human pancreatic cancer cell lines.
Journal: International journal of gastrointestinal cancer 20050101
Title: Imexon-induced apoptosis in multiple myeloma tumor cells is caspase-8 dependent.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20040215
Title: Chemical basis for the biological activity of imexon and related cyanoaziridines.
Journal: Journal of medicinal chemistry 20040101
Title: Cytotoxic effects of B lymphocytes mediated by reactive oxygen species.
Journal: Current pharmaceutical design 20040101
Title: Imexon activates an intrinsic apoptosis pathway in RPMI8226 myeloma cells.
Journal: Anti-cancer drugs 20021101
Title: Molecular and cellular characterization of imexon-resistant RPMI8226/I myeloma cells.
Journal: Molecular cancer therapeutics 20020101
Title: Induction of mitochondrial changes in myeloma cells by imexon.
Journal: Blood 20010601
Title: Induction of oxidative stress and apoptosis in myeloma cells by the aziridine-containing agent imexon.
Journal: Biochemical pharmacology 20000915
Title: Antiproliferative and antitumor activity of the 2-cyanoaziridine compound imexon on tumor cell lines and fresh tumor cells in vitro.
Journal: Journal of the National Cancer Institute 19920819
Title: Antiviral efficacy of Imexon in the Rauscher murine retrovirus AIDS model.
Journal: Immunopharmacology and immunotoxicology 19900101
Title: Sheveleva EV, et al. Imexon induces an oxidative endoplasmic reticulum stress response in pancreatic cancer cells. Mol Cancer Res. 2012 Mar;10(3):392-400.
Title: Samulitis BK, et al. Interaction of dacarbazine and imexon, in vitro and in vivo, in human A375 melanoma cells. Anticancer Res. 2011 Sep;31(9):2781-5.
Title: Roman NO, et al. Imexon enhances gemcitabine cytotoxicity by inhibition of ribonucleotide reductase. Cancer Chemother Pharmacol. 2011 Jan;67(1):183-92.
